ES2074046T3 - Procedimiento de construccion de una linea celular animal para la preparacion de beta-interferon humano. - Google Patents

Procedimiento de construccion de una linea celular animal para la preparacion de beta-interferon humano.

Info

Publication number
ES2074046T3
ES2074046T3 ES88105895T ES88105895T ES2074046T3 ES 2074046 T3 ES2074046 T3 ES 2074046T3 ES 88105895 T ES88105895 T ES 88105895T ES 88105895 T ES88105895 T ES 88105895T ES 2074046 T3 ES2074046 T3 ES 2074046T3
Authority
ES
Spain
Prior art keywords
beta
ifn
preparation
cell line
animal cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88105895T
Other languages
English (en)
Other versions
ES2074046T5 (es
Inventor
Walter Dr Reiser
Karl-Eduard Dipl-Bioch Joester
Wieland Dr Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RENTSCHLER BIOTECH GmbH
Dr Rentschler Biotechnologie GmbH
Original Assignee
RENTSCHLER BIOTECH GmbH
Dr Rentschler Biotechnologie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6325567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2074046(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by RENTSCHLER BIOTECH GmbH, Dr Rentschler Biotechnologie GmbH filed Critical RENTSCHLER BIOTECH GmbH
Application granted granted Critical
Publication of ES2074046T3 publication Critical patent/ES2074046T3/es
Publication of ES2074046T5 publication Critical patent/ES2074046T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE DESRIBE UN PROCEDIMIENTO PARA LA OBTENCION DE IFN-BETA EN UNA CELULA HUESPED ANIMAL. EL IFN-BETA AISLADO CON ALTO RENDIMIENTO DEL SOPORTE CELULAR POSEE UNA ACTIVIDAD ESPECIFICA DE UNOS 3,8X 10 8 IE/MG DE PROTEINA. LOS ENSAYOS BIOLOGICOS E INMUNOLOGICOS DEMUESTRAN QUE EL IFN-BETA AISLADO ES AMPLIAMENTE IDENTICO CONEL IFN-BETA NATURAL. EL IFN-BETA OBTENIDO CON EL PROCEDIMIENTO DESCRITO ESTA GLICOLIZADO EN UN 95%, COINCIDIENDO AMPLIAMENTE LA GLICOLIZACION,TANTO EN ESTRUCTURA COMO EN SECUENCIA, CON LA DEL IFN-BETA NATURL, AUNQUE NO ES IDENTICA A ELLA.
ES88105895T 1987-04-14 1988-04-13 Procedimiento de construccion de una linea celular animal para la preparacion de beta-interferon humano. Expired - Lifetime ES2074046T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873712564 DE3712564A1 (de) 1987-04-14 1987-04-14 Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta

Publications (2)

Publication Number Publication Date
ES2074046T3 true ES2074046T3 (es) 1995-09-01
ES2074046T5 ES2074046T5 (es) 2002-11-16

Family

ID=6325567

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88105895T Expired - Lifetime ES2074046T5 (es) 1987-04-14 1988-04-13 Procedimiento de construccion de una linea celular animal para la preparacion de beta-interferon humano.

Country Status (6)

Country Link
EP (1) EP0287075B2 (es)
JP (1) JP2798674B2 (es)
AT (1) ATE117372T1 (es)
DE (2) DE3712564A1 (es)
ES (1) ES2074046T5 (es)
GR (1) GR3015689T3 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
EP0551535A1 (en) * 1992-01-13 1993-07-21 SCLAVO S.p.A. Process for the purification of recombinant human beta interferon, beta interferon thus purified, and pharmaceutical compositions which contain them
GB9506051D0 (en) 1995-03-24 1995-05-10 Univ Singapore Gene expression
EP1224940B2 (de) 1997-09-23 2010-08-11 Rentschler Biotechnologie GmbH Flüssige Interferon-Beta Formulierungen
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
HUP0303251A2 (hu) 2001-02-27 2003-12-29 Maxygen Aps Béta-interferon-szerű molekulák
EP2305311A3 (en) * 2001-10-10 2011-07-20 BioGeneriX AG Glycoconjugation of peptides
KR20050059195A (ko) * 2002-09-27 2005-06-17 바이오겐 아이덱 엠에이 인코포레이티드 인터페론-β를 이용한 만성 염증성 탈수초성다발성신경병증의 치료
JP4889505B2 (ja) 2004-02-02 2012-03-07 アンブレツクス・インコーポレイテツド 被修飾されたヒト成長ホルモンポリペプチドおよびこれらの使用
SG155183A1 (en) 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
EP2076533B1 (en) 2007-05-02 2014-10-08 Ambrx, Inc. Modified interferon beta polypeptides and their uses
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties

Also Published As

Publication number Publication date
EP0287075A3 (en) 1990-01-24
ATE117372T1 (de) 1995-02-15
ES2074046T5 (es) 2002-11-16
EP0287075A2 (de) 1988-10-19
GR3015689T3 (en) 1995-07-31
JP2798674B2 (ja) 1998-09-17
DE3712564A1 (de) 1988-11-24
DE3852777D1 (de) 1995-03-02
EP0287075B1 (de) 1995-01-18
EP0287075B2 (de) 2002-04-10
JPS63269987A (ja) 1988-11-08

Similar Documents

Publication Publication Date Title
ES2074046T3 (es) Procedimiento de construccion de una linea celular animal para la preparacion de beta-interferon humano.
ATE140009T1 (de) Interleukin-4 protein mit bcgf- und tcgf- aktivität gegenüber menschlichen zellen (menschliches interleukin-4)
ES2122955T3 (es) Adn que codifica proteinas que se unen a la il-1 humana.
DE10075011I2 (de) Rezeptoren für Tumornekrosisfaktor-alpha und-beta.
FI885679A (fi) Samuttryckning i eukariotiska celler.
ES520358A0 (es) Procedimiento para producir polipeptido
PT83972B (pt) Processo para a preparacao de proteina gm-csf e de seus derivados
BG60238B1 (bg) Човешки тумор- некротизиращ фактор
JPS55131399A (en) Cultivation of namalva cell and replacing animal serum protein by human albumine for producing interferon by said cell
DE3850774D1 (de) Rinder-interleukin-1-alpha.
ATE86298T1 (de) Enzymatisch inaktive, immunologisch aktive beta- galactosidase-muteine.
JPS6420086A (en) Polypeptide and production thereof
AU637589B2 (en) Ancrod proteins, their production and use
EP0219839A3 (de) Derivat des Interleukin-2, seine Herstellung und Verwendung
EP0603393A4 (en) INTERLEUKIN 6 HUMAN RECOMBINATION WITH HOMOGENEOUS N TERMINATION AND PRODUCTION OF THIS INTERLEUKIN.
FI934079A (fi) Menetelmä fuusioproteiinin valmistamiseksi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 287075

Country of ref document: ES